RLAY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RLAY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Relay Therapeutics does not have enough data to calculate 10-Year ROIIC %.
The historical data trend for Relay Therapeutics's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
10-Year ROIIC % | Get a 7-Day Free Trial | - | - | - | - | - |
Relay Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
10-Year ROIIC % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Relay Therapeutics's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Relay Therapeutics's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Relay Therapeutics's 10-Year ROIIC % falls into.
Relay Therapeutics's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
10-Year ROIIC % | = | 10-Year Incremental Net Operating Profit After Taxes (NOPAT)** | / | 10-Year Incremental Invested Capital** |
= | ( -379.422 (Dec. 2023) - (Dec. 2013) ) | / | ( 80.747 (Dec. 2023) - (Dec. 2013) ) | |
= | / | |||
= | N/A%*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Relay Therapeutics (NAS:RLAY) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Thank you for viewing the detailed overview of Relay Therapeutics's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Rahmer | officer: See remarks | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139 |
Thomas Catinazzo | officer: Vice President, Finance | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Donald A Bergstrom | officer: See Remarks | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Brian Adams | officer: General Counsel | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Sanjiv Patel | director, officer: President and CEO | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Andy Porter | officer: See Remarks | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Mark Murcko | director | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Sekar Kathiresan | director | 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Third Rock Ventures Iii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Jami Rubin | director | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Douglas S Ingram | director | 2525 DUPONT DR, IRVINE CA 92612 |
Third Rock Ventures Gp Iv, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Svf Pauling (cayman) Ltd | 10 percent owner | 27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008 |
Picularium, Llc | 10 percent owner | 1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036 |
Laura Shawver | director | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
From GuruFocus
By Value_Insider Value_Insider • 11-03-2022
By Marketwired • 09-18-2023
By sperokesalga sperokesalga • 05-25-2023
By sperokesalga sperokesalga • 04-27-2023
By PurpleRose PurpleRose • 07-15-2022
By PurpleRose PurpleRose • 08-18-2022
By GuruFocus Research GuruFocus Editor • 02-01-2023
By sperokesalga sperokesalga • 05-24-2023
By sperokesalga sperokesalga • 04-19-2023
By sperokesalga sperokesalga • 02-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.